Prolonged low-dose infusion for gemcitabine: a systematic review

References

• Aspeslagh S, Stein M, Bahleda R, et al. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anticancer Drugs. 2016;28(3):341–349. doi:10.1097/CAD.0000000000000457
   Web of Science ®Google Scholar
• Cattel L, Airoldi M, Delprino L, et al. Pharmacokinetic evaluation of gemcitabine and 2ʹ,2ʹ-difluorodeoxycytidine-5ʹ-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol. 2006;17:142~147.
   PubMed Web of Science ®Google Scholar
• Sugiyama E, Kaniwa N, Kim SR, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet. 2010;49(8):549–558. doi:10.2165/11532970-000000000-0000020608756
   PubMed Web of Science ®Google Scholar
• Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. Invest New Drugs. 2005;23(2):139–146. doi:10.1007/s10637-005-5859-415744590
   PubMed Web of Science ®Google Scholar
• Fossela FV, Lipman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15:310–316. doi:10.1200/JCO.1997.15.1.3108996158
   PubMed Web of Science ®Google Scholar
• Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs. 1997;15(2):115–121.9220290
   PubMed Web of Science ®Google Scholar
• Maurel J, Zorrilla M, Puertolas T, et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs. 2001;12(9):713–717.11593051
   PubMed Web of Science ®Google Scholar
• Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hr infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer. 1996;74(3):460–462. doi:10.1038/bjc.1996.3828695365
   PubMed Web of Science ®Google Scholar
• Dehua Z, Mingming C, Jisheng W, Addison CL. Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer. PLoS One. 2018;13(3):e0193814. doi:10.1371/journal.pone.019381429561887
   PubMed Web of Science ®Google Scholar
• Beniwal SK, Patel KM, Shukla S, et al. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer. Indian J Cancer. 2012;49(2):202–208. doi:10.4103/0019-509X.10286123107971
   PubMed Web of Science ®Google Scholar
• Martina V, Matjaz Z, Tanja B, et al. Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial. Radiol Oncol. 2014;48(4):369–380.25435850
   PubMed Web of Science ®Google Scholar
• Matjaz Z, Viljem K, Smrdel U, et al. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-smallcell lung cancer: a Randomized Phase II Clinical Trial. Thorac Oncol. 2009;4:1148–1155. doi:10.1097/JTO.0b013e3181ae280f
   PubMed Web of Science ®Google Scholar
• Zwitter M, Kovac V, Rajer M, et al. Two schedules of chemotherapy for patients with non- small cell lung cancer in poor performance status: a phase II randomized trial. Anticancer Drugs. 2010;21:662–668. doi:10.1097/CAD.0b013e32833ab7a020453635
   PubMed Web of Science ®Google Scholar
• Wu ZY, Guan HH, Lin ZX, et al. Combination of low-dose gemcitabine in 6 hr infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer. J Chemother. 2014;26(5):306–311. doi:10.1179/1973947813Y.000000013924075685
   PubMed Web of Science ®Google Scholar
• Narayanan P, Prabhash K, Kurkure P, Parikh P. Treatment of advanced NSCLC (Stage IIIB and IV) with low dose gemcitabine and carboplatin-indian experience. Lung Cancer. 2009;64:S57. doi:10.1016/S0169-5002(09)70260-0
   Web of Science ®Google Scholar
• Xiong JP, Feng M, Qiu F, et al. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer. 2008;60(2):208–214. doi:10.1016/j.lungcan.2007.10.00418023915
   PubMed Web of Science ®Google Scholar
• Zwitter M, Kovac V, Smrdel U, et al Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer. 2005;16(10):1129–1134.
   Google Scholar
• Kovac V, Zwitter M, Rajer M, et al. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs. 2012;23(2):230–238. doi:10.1097/CAD.0b013e32834d7a1c22027538
   PubMed Web of Science ®Google Scholar
• Arrieta O, López-Macías D, Mendoza-García VO, et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014;73(5):975–982. doi:10.1007/s00280-014-2429-524687408
   PubMed Web of Science ®Google Scholar
• Khaled H, Emara ME, Gaafar RM, et al. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol Oncol Semin Ori Invest. 2008;26(2):133–136. doi:10.1016/j.urolonc.2007.01.013
   PubMed Web of Science ®Google Scholar
• Khaled H, Abutaleb F, Haggag R, et al. Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial. Med Oncol. 2014;31(1):1–6.
   Web of Science ®Google Scholar
• Guan HH, Yang HK, Zhou L, et al. Clinical observation prolonged infusion of low-dose gemcitabine combined with nedaplatin in treatment of recurrent/metastatic nasopharyngeal carcinoma. New Med. 2014;45(8):555–557.
   Google Scholar
• Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24 hr infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003;21(5):690–694.14628426
   PubMed Web of Science ®Google Scholar
• von Delius DS, Lersch C, Schultefrohlinde E, Mayr M, Schmid RM, Eckel F. Phase II trial of weekly 24 hr infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer. 2005;5(1):61. doi:10.1186/1471-2407-5-6115949047
   PubMedGoogle Scholar
• Schmid P, Krocker J, Jehn C, et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol. 2005;16(10):1624–1631. doi:10.1093/annonc/mdi32116030028
   PubMed Web of Science ®Google Scholar
• Schmid P, Akrivakis K, Flath B, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs. 1999;10(7):625–631.10507311
   PubMed Web of Science ®Google Scholar
• Schmid P, Heilmann V, Schulz CO, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol. 2005;131(9):568–574. doi:10.1007/s00432-005-0675-y16044345
   PubMed Web of Science ®Google Scholar
• Späth-Schwalbe SE, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs. 2000;11(5):325–329. doi:10.1097/00001813-200006000-0000210912948
   PubMed Web of Science ®Google Scholar
• Zwitter M, Kovac V, Smrdel U, et al. Phase I–II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs. 2005;16:1129–1134.16222156
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist. 2008;13(3):261–276. doi:10.1634/theoncologist.2007-021518378536
   PubMed Web of Science ®Google Scholar
• Metharom E, Galettis P, Manners S, et al. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia Pac J Clin Oncol. 2011;7(1):65–74. doi:10.1111/j.1743-7563.2010.01354.x21332653
   PubMed Web of Science ®Google Scholar